Transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma: A systematic review.

Norero, Blanca; Bosch, Jaume; Berzigotti, Annalisa; Rodrigues, Susana G (2023). Transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma: A systematic review. United European gastroenterology journal, 11(8), pp. 733-744. Wiley 10.1002/ueg2.12454

[img]
Preview
Text
UEG_Journal_-_2023_-_Norero.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (2MB) | Preview

BACKGROUND/AIMS

Transjugular intrahepatic portosystemic shunts (TIPS) in patients with hepatocellular carcinoma (HCC) may improve access to curative therapies, treat portal hypertension (PH)-related complications without worsening liver function, and increase overall survival. Data on the efficacy and safety of TIPS to treat PH complications in HCC patients, as well as the HCC treatment response, were evaluated.

METHODS

Studies reporting efficacy in controlling bleeding/ascites or response to HCC therapy, safety, and survival in patients with HCC and TIPS were searched systematically on PubMed and Embase. An extraction of articles using predefined data fields and quality indicators was used.

RESULTS

We selected 19 studies and found 937 patients treated for ascites/bleeding and 177 evaluating HCC treatment response. Over half were under 5 cm and solitary lesions, and most studies included tumours with portal vein thrombosis. Regarding PH studies, TIPS resolved bleeding/ascites in >60% of patients, more effective for bleeding. There were no lethal complications reported and procedural bleeding occurred in <5%. Hepatic encephalopathy occurred in 15%-30% within three months. In the HCC treatment-response studies, major complication rates were low with no mortality. In the studies that evaluated the response to transarterial chemoembolization, complete response rate of patients with TIPS varied from 16% to 75%. Liver transplantation rate varied from 8% to 80%, with >40% rate in half of the studies.

CONCLUSIONS

In the published studies, TIPS is effective in treating PH complications in patients with HCC. Prospective studies on TIPS placement in patients with HCC are urgently needed to evaluate the efficacy and safety of TIPS in this setting.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology

UniBE Contributor:

Bosch Genover, Jaime, Berzigotti, Annalisa, Gomes Rodrigues, Susana

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2050-6414

Publisher:

Wiley

Language:

English

Submitter:

Pubmed Import

Date Deposited:

25 Sep 2023 14:00

Last Modified:

25 Mar 2024 09:10

Publisher DOI:

10.1002/ueg2.12454

PubMed ID:

37736854

Uncontrolled Keywords:

HCC TIPS cirrhosis hepatocellular carcinoma liver cancer portal hypertension

BORIS DOI:

10.48350/186532

URI:

https://boris.unibe.ch/id/eprint/186532

Actions (login required)

Edit item Edit item
Provide Feedback